// App-Quantinova.ai

3208 : Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Researchers

Presenter

  • Xavier Leleu

Principal Investigators

  • Borhane Slama

  • Renato Zambello

  • Sorina Nicoleta Badelita

  • Eirini Katodritou

  • Jo Caers

  • Thomas Khr

  • Florence Suzan

  • Abeera Mohammad

  • Sally Wetten

  • Evangelos Terpos

Medical Centers

  • Department of Oncology-Haematology and Cell Therapy, CHU, Poitiers, INSERM, Inserm CIC 1402, Poitiers, France, Poitiers, France

  • Service d'Hématologie, Centre Hospitalier d'Avignon,Avignon,Francia

  • Hematology and Clinical Immunology, Department of Medicine, Azienda Ospedaliera di Padova,Padova,Italy

  • Hematology,Institutul Clinic Fundeni,Bucharest,Romania

  • Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece

  • Department of Gastroenterology, CHU de Liege, Liege, Belgium

  • Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria

  • Amgen (Europe) GmbH, Zug, Switzerland

  • Global Biostatistical Science, Amgen Ltd, Uxbridge, United Kingdom

  • Centre for Observational Research,Amgen Ltd.,Uxbridge,United Kingdom

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

Locations

  • France

  • Italy

  • Romania

  • Greece

  • Belgium

  • Austria

  • Switzerland

  • United Kingdom

Companies

  • Amgen (Europe) GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • carfilzomib Intravenous

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT03091127

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved